Companion Diagnostics Market, By Technology Type (Real Time-Polymerase Chain Reactions (PCR), Gene Sequencing, Fluorescence in situ Hybridization, and Others) By Application (Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Diseases an

Companion Diagnostics Market, By Technology Type (Real Time-Polymerase Chain Reactions (PCR), Gene Sequencing, Fluorescence in situ Hybridization, and Others) By Application (Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Diseases and Others), By End User (Hospitals, Research Laboratories, Biopharmaceutical companies, and Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Companion diagnostics are medical devices that are used to detect specific biomarkers or genes in patients that help determine which patients are most suitable candidates for a particular therapy. These diagnostics play an important role in personalized healthcare by helping physicians select appropriate targeted treatment options for cancer and other diseases. Companion diagnostics tests evaluate the expression of biomarkers, such as proteins, genes or chromosomes that plays a role in a patient’s response to a specific drug. By analyzing the expression levels of such biomarkers, these tests help to identify whether a particular drug would be safe and effective for a specific patient or set of patients with a given disease. This enables better therapeutic outcomes by ensuring only suitable patients receive specialized treatments.

Market Dynamics:

Global companion diagnostics market is driven by rising demand for personalized medicine, growth in molecular diagnostics, increasing approvals of new targeted therapies & companion diagnostics, technological advancements, and growing incidence and prevalence of cancer, and other chronic diseases. However, the market growth can be restricted by high pricing pressure and regulatory hassles that are involved in developing and commercializing these molecular diagnostic tests. Key opportunities in this market include developing biomarkers and companion diagnostics for immunotherapies, expanding applications in non-oncology diseases, precision medicine collaborations between In vitro diagnostics (IVD) companies and drug makers, growing focus on companion diagnostic development in emerging markets, and adoption of advanced technologies like Next-generation sequencing (NGS) for biomarker detection.

Key features of the study:

• This report provides in-depth analysis of the global companion diagnostics market, and provides market size (US$ Bn)and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global companion diagnostics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F. Hoffmann-La Roche AG, Agilent Technologies, Inc., QIAGEN N.V, Abbott Laboratories, Inc., Almac Group, Danaher Corporation, Illumina, Inc., bioMérieux SA, Myriad Genetics, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Abnova Corporation, Guardant Health, Inc., Icon Plc., and Biogenex Laboratories, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global companion diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global companion diagnostics market

Detailed Segmentation:

• Global Companion Diagnostics Market, By Technology Type
• Real Time-Polymerase Chain Reactions (PCR
• Gene Sequencing
• Fluorescence in situ Hybridization
• Others
• Global Companion Diagnostics Market, By Application
• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Neurological Diseases
• Others
• Global Companion Diagnostics Market, By End User
• Hospitals
• Research Laboratories
• Biopharmaceutical companies
• Others
• Global Companion Diagnostics Market, By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Top Companies in Global Companion Diagnostics Market:
• F.Hoffmann-La Roche AG
• Agilent Technologies, Inc.
• QIAGEN N.V
• Abbott Laboratories, Inc.
• Almac Group
• Danaher Corporation
• Illumina, Inc.
• bioMérieux SA
• Myriad Genetics, Inc.
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• Abnova Corporation
• Guardant Health, Inc.
• Icon Plc.
• Biogenex Laboratories, Inc.